• 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Chimie Nouvelle >Large ring bridged B-lactams: design of novel antibiotics
【24h】

Large ring bridged B-lactams: design of novel antibiotics

机译：大环桥B-内酰胺：新型抗生素的设计

获取原文
获取原文并翻译 | 示例
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

When they were introduced into the health care system in the early 1940s., penicillins (i.e. the β-lactam antibiotics) were considered as "magic drugs". In fact, at the beginning of the 20th century, about one third of the deaths were caused by infectious diseases and the advent of the antibiotics enabled to save millions of lives and enhanced life expectancy. However, since the introduction of penicillins, bacteria counteract their action, leading to a worrisome situation about antibiotics efficiency. A major example of the increasing resistance of bacteria over the recent years is the occurrence of methicillin-resistant Staphylococcus aureus (MRSA), the most important cause of antibiotic-resistant healthcare-associated infections worldwide, which in 2005, in the United States was responsible of more deaths than AIDS (18 650 compared to 16 000). Therefore the research of novel antibiotics is a matter of utmost importance.
机译：在1940年代初期将它们引入医疗保健系统时，青霉素（即β-内酰胺类抗生素）被认为是“神奇药物”。实际上，在20世纪初，约有三分之一的死亡是由传染病引起的，抗生素的出现使人们得以挽救数百万的生命并延长了预期寿命。但是，由于引入了青霉素，细菌抵消了它们的作用，导致令人担忧的抗生素效率状况。近年来，细菌耐药性增加的一个重要例子是耐甲氧西林金黄色葡萄球菌（MRSA）的出现，这是全球耐药性医疗保健相关感染的最重要原因，2005年在美国引起了这种情况死亡人数比艾滋病多（18 650比16 000）。因此，新型抗生素的研究至关重要。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号